Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005938 · ClinicalTrials.gov registry record · Phase 2
DX-8951f in Treating Patients With Biliary Cancer
A Phase 2 study of Liver Cancer and Gallbladder Cancer, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Study locations
NCT00005938: Completed Phase 2 study of Liver Cancer and Gallbladder Cancer, sponsored by Daiichi Sankyo.
NCT00005938 is a Phase 2 study of Liver Cancer and Gallbladder Cancer that has completed, run by Daiichi Sankyo. The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005938, a Phase 2 study of Liver Cancer and Gallbladder Cancer, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have biliary cancer.
Conditions Studied
Interventions
- DRUG exatecan mesylate
Study Locations (5)
Texas
- Simmons Cancer Center - Dallas - Dallas
- University of Texas - MD Anderson Cancer Center - Houston
- Cancer Therapy & Research Center - San Antonio
Colorado
- University of Colorado Cancer Center - Denver
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-03 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
What the finished NCT00005938 record still lists
NCT00005938 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 3 conditions, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which exatecan mesylate is the first listed.
NCT00005938 lists 5 locations in 3 states (Texas, Colorado, New York).
Frequently Asked Questions
What is clinical trial NCT00005938 about?
NCT00005938 is a clinical study titled "DX-8951f in Treating Patients With Biliary Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have biliary cancer.
What is the current status of trial NCT00005938?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-03. Estimated completion is 2005-04.
What conditions does trial NCT00005938 study?
This clinical trial studies the following conditions: Liver Cancer, Gallbladder Cancer, Extrahepatic Bile Duct Cancer.
What interventions are being tested in trial NCT00005938?
The interventions under investigation include: exatecan mesylate (DRUG).
Who is sponsoring clinical trial NCT00005938?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005938 being conducted?
This trial has 5 study locations across Colorado, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
RECRUITING · Phase 2
-
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
Y-90 Treatment Response Using Transarterial Radioembolization
RECRUITING · Phase 2
-
Domvanalimab and Zimberelimab in Advanced Liver Cancers
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia